Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Bicara Therapeutics Inc. (NASDAQ:BCAX) has received a consensus recommendation of “Moderate Buy” from the ten ratings firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $30.25.

A number of equities analysts recently weighed in on BCAX shares. Citizens Jmp began coverage on shares of Bicara Therapeutics in a research note on Thursday, January 29th. They set a “market perform” rating and a $31.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Friday, January 9th. BTIG Research reiterated a “buy” rating on shares of Bicara Therapeutics in a report on Thursday, January 15th. UBS Group reissued a “buy” rating on shares of Bicara Therapeutics in a research report on Wednesday, January 14th. Finally, HC Wainwright reissued a “buy” rating on shares of Bicara Therapeutics in a research note on Wednesday, January 14th.

Insiders Place Their Bets

In other news, insider David Raben sold 16,300 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $18.52, for a total transaction of $301,876.00. Following the completion of the sale, the insider owned 55,286 shares of the company’s stock, valued at $1,023,896.72. This trade represents a 22.77% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Ivan Hyep sold 2,963 shares of Bicara Therapeutics stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $18.25, for a total transaction of $54,074.75. Following the completion of the sale, the chief financial officer owned 145,355 shares of the company’s stock, valued at $2,652,728.75. This represents a 2.00% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 128,769 shares of company stock valued at $2,415,814. Company insiders own 15.50% of the company’s stock.

Institutional Investors Weigh In On Bicara Therapeutics

Large investors have recently bought and sold shares of the stock. AQR Capital Management LLC bought a new stake in Bicara Therapeutics in the first quarter valued at $248,000. Woodline Partners LP boosted its position in shares of Bicara Therapeutics by 26.5% during the 1st quarter. Woodline Partners LP now owns 348,690 shares of the company’s stock worth $4,543,000 after purchasing an additional 72,998 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Bicara Therapeutics by 36.8% during the 2nd quarter. Geode Capital Management LLC now owns 672,485 shares of the company’s stock worth $6,248,000 after purchasing an additional 180,833 shares in the last quarter. Police & Firemen s Retirement System of New Jersey grew its stake in shares of Bicara Therapeutics by 119.6% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 8,109 shares of the company’s stock valued at $75,000 after buying an additional 4,417 shares during the period. Finally, Intech Investment Management LLC grew its stake in shares of Bicara Therapeutics by 65.3% in the 2nd quarter. Intech Investment Management LLC now owns 27,673 shares of the company’s stock valued at $257,000 after buying an additional 10,927 shares during the period.

Bicara Therapeutics Stock Performance

Shares of NASDAQ BCAX opened at $18.41 on Friday. The company has a market capitalization of $1.01 billion, a P/E ratio of -8.22 and a beta of -0.78. Bicara Therapeutics has a 52-week low of $7.80 and a 52-week high of $20.25. The company’s 50 day moving average price is $16.98 and its 200-day moving average price is $16.27.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.